A 2-year-old girl from Delhi presents with a 2-month history of progressive abdominal distension and irritability. Her mother reports that she has lost weight and has had intermittent fever. On examination, the child is pale and has a firm, fixed mass in the left upper abdomen that crosses the midline. Laboratory investigations show hemoglobin 8.5 g/dL, platelet count 450,000/μL, and elevated 24-hour urine vanillylmandelic acid (VMA). Chest X-ray reveals a left-sided mediastinal mass. What is the most likely diagnosis?

Explanation

## Neuroblastoma: Diagnosis and Clinical Presentation ### Case Analysis This 2-year-old girl presents with a constellation of findings highly suggestive of **neuroblastoma with metastatic disease**: | Finding | Significance | |---------|-------------| | Age 2 years | Peak incidence of neuroblastoma (median age 2–3 years) | | Firm, fixed, crosses midline | Typical of retroperitoneal neuroblastoma | | Elevated VMA in 24-hour urine | Pathognomonic for catecholamine-secreting tumor (neuroblastoma) | | Mediastinal mass on CXR | Neuroblastoma commonly arises from sympathetic chain; 25% are thoracic | | Anemia + thrombocytosis | Paraneoplastic syndrome; elevated platelets suggest advanced disease | | Weight loss, fever, irritability | Constitutional symptoms of advanced malignancy | ### Key Point: Neuroblastoma Pathophysiology **Mnemonic: NEUROBLASTOMA** — **N**eural crest origin, **E**levated catecholamines, **U**nder age 5, **R**etroperitoneal/mediastinal, **O**ften metastatic at diagnosis, **B**one/bone marrow involvement, **L**iver metastases, **A**drenaline metabolites (VMA/HVA), **S**ympathetic chain, **T**umor heterogeneity, **O**ncogene MYCN amplification, **M**etastatic disease in 50% at diagnosis, **A**ge-dependent prognosis **High-Yield:** Neuroblastoma is a neural crest-derived tumor of the sympathetic nervous system. It arises from: - Adrenal medulla (40%) - Paraspinal sympathetic ganglia (60%) ### Diagnostic Criteria Met 1. **Elevated VMA (Vanillylmandelic Acid)** - Metabolite of catecholamine (norepinephrine) breakdown - Present in 90% of neuroblastomas - Highly specific for neuroendocrine tumors - Wilms tumor does NOT elevate VMA 2. **Location and Imaging** - Retroperitoneal mass crossing midline → sympathetic chain origin - Mediastinal mass → thoracic sympathetic chain - Bilateral involvement suggests advanced disease 3. **Hematologic Findings** - Anemia: from bone marrow infiltration or chronic disease - Thrombocytosis: paraneoplastic (IL-6 mediated) - Suggests metastatic disease 4. **Age and Presentation** - Neuroblastoma: median age 2–3 years (this child is 2) - Wilms tumor: median age 3–4 years - Neuroblastoma more common in very young children ### Staging and Prognosis **Clinical Pearl:** This child has **Stage 4 neuroblastoma** (metastatic disease): - Unilateral primary with contralateral metastases (abdominal + mediastinal + bone marrow) - 5-year survival for Stage 4: ~50% (depends on MYCN status, age, histology) - Stage 4S (metastatic only to liver/skin/bone marrow in infants < 18 months) has better prognosis ### Why Not Wilms Tumor? **Warning:** Wilms tumor commonly presents as an abdominal mass in young children, but: - **VMA is NOT elevated** — Wilms is a renal embryonal tumor, not neuroendocrine - Mediastinal involvement is extremely rare in Wilms tumor - Thrombocytosis is not typical of Wilms tumor - Wilms tumor typically presents with hematuria or abdominal distension alone ### Diagnostic Flowchart ```mermaid flowchart TD A[Young child with abdominal mass]:::outcome --> B{Elevated VMA/HVA?}:::decision B -->|Yes| C[Neuroblastoma]:::outcome B -->|No| D{Hematuria present?}:::decision D -->|Yes| E[Wilms tumor]:::outcome D -->|No| F{Mediastinal involvement?}:::decision F -->|Yes| G[Lymphoma or germ cell tumor]:::outcome F -->|No| H[Other abdominal malignancy]:::outcome C --> I[Confirm with MIBG scan, bone marrow, MYCN status]:::action ``` ### Confirmatory Investigations **High-Yield:** Next steps include: 1. **MIBG (Metaiodobenzylguanidine) scintigraphy** — detects catecholamine-secreting tissue; highly sensitive for neuroblastoma 2. **Bone marrow biopsy** — assess for metastatic involvement 3. **MYCN amplification status** — prognostic marker; amplification = poor prognosis 4. **Histology** — after biopsy or surgery; determines risk stratification 5. **Imaging:** CT chest/abdomen/pelvis, skeletal survey or bone scan [cite:Pediatric Oncology (COG Neuroblastoma Protocol), Harrison 21e Ch 395]